The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant - Takeaways - MDSpire

The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant

  • By

  • Saurabh Zanwar

  • Eapen K. Jacob

  • Carl Greiner

  • Kevin Pavelko

  • Michael Strausbauch

  • Emilie Anderson

  • Arini Arsana

  • Megan Weivoda

  • Mithun Vinod Shah

  • Taxiarchis Kourelis

  • September 26, 2023

  • 0 min

Share

  • 1

    Autologous stem cell transplantation (ASCT) is a key treatment for multiple myeloma (MM), yet most patients experience relapse post-transplant.

  • 2

    Therapy-related myeloid neoplasms (t-MN) occur in 2-4% of MM patients post-ASCT and are linked to poor survival outcomes.

  • 3

    Pre-existing immune abnormalities in mobilized peripheral blood stem cells (PBSC) may lead to an immunosuppressive tumor microenvironment.

  • 4

    Increased T-cell exhaustion and immune senescence correlate with poor outcomes after ASCT and novel therapies in MM.

  • 5

    The study explores the immune composition of mobilized PBSC to predict relapse and t-MN development in MM patients.

Original Source(s)

The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant

  • by Saurabh Zanwar, Eapen K. Jacob, Carl Greiner, Kevin Pavelko, Michael Strausbauch, Emilie Anderson, Arini Arsana, Megan Weivoda, Mithun Vinod Shah, Taxiarchis Kourelis

  • September 26, 2023

Related Content

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders